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ABSTRACT
Lysophosphatidic acid (LPA), a prototypical ligand for G protein coupled 
receptors, and Forkhead box protein M1 (FOXM1), a transcription factor that regulates 
expression of a wide array of genes involved in cancer initiation and progression, are 
two important oncogenic signaling molecules in human epithelial ovarian cancers 
(EOC). We conducted in vitro mechanistic studies using pharmacological inhibitors, 
genetic forms of the signaling molecules, and RNAi-mediated gene knock-down to 
uncover the molecular mechanisms of how these two molecules interact in EOC 
cells. Additionally, in vivo mouse studies were performed to confirm the functional 
involvement of FOXM1 in EOC tumor formation and progression. We show for the first 
time that LPA up-regulates expression of active FOXM1 splice variants in a time- and 
dose-dependent manner in the human EOC cell lines OVCA433, CAOV3, and OVCAR5. 
Gi-PI3K-AKT and G12/13-Rho-YAP signaling pathways were both involved in the LPA 
receptor (LPA1–3) mediated up-regulation of FOXM1 at the transcriptional level. In 
addition, down-regulation of FOXM1 in CAOV3 xenografts significantly reduced tumor 
and ascites formation, metastasis, and expression of FOXM1 target genes involved in 
cell proliferation, migration, or invasion. Collectively, our data link the oncolipid LPA, 
the oncogene YAP, and the central regulator of cell proliferation/mutagenesis FOXM1 
in EOC cells. Moreover, these results provide further support for the importance of 
these pathways as potential therapeutic targets in EOC.
INTRODUCTION
Despite the pathological and genetic heterogeneity, 
high-grade serous ovarian carcinomas (HGSC) share 
common molecular alterations. In addition to TP53, 
integrated HGSC studies identified that forkhead box M1 
(FOXM1) transcription factor network is significantly 
altered in 84% of HGSC cases [1, 2].
The FOXM1 protein is a proliferation-specific 
transcription factor that plays a key role in controlling 
expression of cell cycle genes essential for tumorigenesis 
[3]. Overexpression of FOXM1 and its potential 
correlations to worse prognosis and/or drug-resistance in 
epithelial ovarian cancer (EOC) have been reported by 
several labs [1, 2, 4–6]. Lok et al have shown that the 
overexpressed phospho-ERK and FOXM1 are correlated 
well and they are significantly correlated to HGSC 
with aggressive behavior [7]. In addition, inhibition of 
FOXM1 expression by either thiostrepton, a selective 
FOXM1 inhibitor, which may inhibit FOXM1 at the 
transcriptional, post-transcriptional, as well as its promoter 
binding levels [8–11], or U0126 could significantly impair 
FOXM1-mediated oncogenic capacities [12]. Moreover, 
overexpression of FOXM1 predicts poor prognosis and 
FOXM1 promotes proliferation, migration and invasion 
in the EOC cell line HO-8910 in vitro [5, 13]. However, 
the concept of targeting FOXM1 in EOC needs to be 
tested further since the mouse model and reagents used 
may improperly address the targeting issues related to 
FOXM1, due to the potential off-target effects induced by 
the inhibitor, the non-HGSC nature of the cell line used 
(A2780 or SKOV3), or the route of injection (s.c.) [5, 14]. 
In particular, FOXM1’s role in endothelial cells and other 
host cells as reported [15] may complicate the anticancer 
strategies targeting FOXM1 and suggests that specific 
tumor cells targeting is necessary.
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Since FOXM1 displays a strictly proliferation-
specific expression pattern, its expression is up-regulated 
by proliferation signals, but down-regulated by anti-
proliferation signals, in particular, proto-oncoproteins 
(such as AKT and Ras) and growth factors and/or their 
receptors [such as epidermal growth factor receptors 
(EGFRs) and hepatocyte growth factor receptor (HGFR)] 
[3]. Interestingly, YAP (yes-associated protein) has been 
shown to be able to directly induce the transcription of 
CCND1 and FOXM1 via the YAP-TEAD binding site in 
the FOXM1 promoter in malignant mesothelioma (MM) 
cells [16]. Surprisingly, there is no follow-up publication 
in YAP-regulated FOXM1 in any other cell types, in spite 
of the clear emerging attention to the roles of the Hippo-
YAP pathway in various cancers [17–19]. In addition, 
the potential regulation of FOXM1 by G protein coupled 
receptors (GPCRs) and their ligands have not been 
demonstrated in any cell type.
We and others show that lysophosphatidic acid (LPA), 
a small bioactive phospholipid, is elevated in the blood 
of EOC patients [20] and it stimulates cell proliferation, 
migration, invasion, angiogenesis, and tumor metastasis of 
EOC [21–23]. LPA has been considered as an oncolipid and 
an important target for EOC treatment [23–25]. LPA mediated 
its functions via its G protein coupled receptor (GPCR) 
LPA
1–6
 [26]. LPA
1–3
 receptors are functionally involved in 
EOC cells [18, 27–30]. We have recently shown that LPA 
dose- and time-dependently induced YAP dephosphorylation 
(dpYAP) in human EOC cell lines OVCA433, OVCAR5, 
CAOV3, and Monty-1, accompanied by increased YAP 
nuclear translocation and activation [18].
To determine whether LPA itself, which is a 
prototype for GPCR signaling, is able to regulate FOXM1 
in cells, we conducted both in vitro and in vivo mechanistic 
and functional studies in several EOC cell lines. In 
addition, we tested the functional involvement of FOXM1 
in vivo using a xenograft mouse model. Our work has 
functionally linked the oncolipid LPA, the oncogene YAP, 
and the central regulator of cell proliferation/mutagenesis 
FOXM1 in EOC cells.
RESULTS
LPA induced FOXM1 up-regulation in EOC cells
The potential regulation of FOXM1 by GPCRs 
and their ligands were tested using LPA activation, since 
it is a potent inducer of GPCR signaling pathways and 
a well-known oncolipid of EOC. LPA dose- and time-
dependently up-regulated FOXM1 in OVCA433 cells, 
with 10 μM of LPA and 6 hr incubation as the optimal 
conditions for the induction (Figures 1A and 1B). This 
effect inversely correlated to LPA’s effect on pYAP. LPA-
induced de-phosphorylation of YAP (dpYAP and activation 
of YAP) occurred prior to FOXM1 up-regulation (starting 
at 2 hr, Figure 1A) [18]. The quantitative assay results of 
three repeated experiments are shown in the bar format in 
Figures 1A and 1B. YAP was successfully down-regulated 
by specific siRNA (Figure 1C), which blocked LPA-induced 
FOXM1 up-regulation, indicating that YAP was functionally 
involved in LPA-induced FOXM1 up-regulation.
LPA1–3 receptors and both of the PI3K and 
Rho pathways were involved in LPA-induced 
FOXM1 up-regulation
To identify the signaling pathways involved in LPA-
induced FOXM1 expression, we first tested the effect of 
Ki16425, a selective inhibitor for LPA receptors LPA
1
/
LPA3 and Y27632, a selective inhibitor of the Rho-kinase 
(ROCK). As shown in Figures 2A and 2B, although these 
two inhibitors increased the basal levels of FOXM1 
(possibly due to an unknown non-specific effect), they 
blocked the LPA-induced up-regulation of FOXM1. To 
test the potential involvement of LPA receptors more 
specifically, we used siRNAs to block LPA
1
, LPA
2
, and 
LPA3, respectively. The efficacy and specificity of these 
siRNAs have been shown in our recent publication [18]. 
The results shown in Figure 2B suggest that all three LPA 
receptors are involved in LPA’s action on FOXM1.
LPA receptors activate Gi, Gq, and G12/13 [26]. We 
found that pertussis toxin (PTX, 100 ng/mL), a selective 
inhibitor of Gi protein; LY294002, a selective inhibitor of 
PI3K (LY, 10 μM); U0126 (10 μM), a selective inhibitor 
of the kinase of ERK1/2; and MK2203 (MK, 1 μM), a 
selective inhibitor of AKT, significantly inhibited both 
the basal and the LPA-induced FOXM1 expression 
(Figure 2C), suggesting the Gi-PI3K-ERK-AKT pathway 
is involved in LPA-induced FOXM1 up-regulation.
LPA is also a potent inducer of activation of G
12/13
 
and we have shown that the G
12/13
-Rho-ROCK-protein 
phosphatase 1A (PP1A) pathway is involved in LPA-induced 
YAP activation in OVC433 cells [26]. Hence, we tested a 
few blockers in this pathway. As expected, both okadaic 
acid (OA; 100 nM), an inhibitor of PP1A, and the Rho 
inhibitor C3 transferase (C3, 1 μg/mL) blocked LPA-induced 
FOXM1 expression (Figure 2D). In contrast, H89 (10 μM), 
an inhibitor of protein kinase A (PKA), a downstream effector 
of Gs, did not block the LPA’s inducible effect (Figure 2D).
The effects of dominant forms of G
q
, G
12
, and 
G
13
 were tested. G
13
 was involved in LPA’s induction of 
FOXM1. On the other hand, G
12
 and G
q
 were much less or 
not involved (Figure 2E). Among small G proteins, RhoA 
and RhoB were likely to be involved (Figure 2F). These 
experiments were repeated at least three times and similar 
results were obtained.
LPA regulated FOXM1 at the transcriptional 
level
Human FOXM1 is expressed in three distinct splice 
variants FOXM1A, FOXM1B, and FOXM1C [3]. These 
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FOXM1 isoforms display the same DNA-binding specificity 
and bind to DNA-binding sites with the consensus 
sequence 5′-A-C/T-AAA-C/T-AA-3′. While FOXM1A 
is a transcriptional suppressor, FOXM1B and FOXM1C 
are functionally similar and both are transcriptional 
activators [12]. LPA-induced FOXM1 was blocked by both 
actinomycin D (ActD, 1 μg/mL) and cyclohexamine (CHX, 
20 μg/mL) in OVCA433 cells (Figure 3A), suggesting that 
the regulation is at the transcriptional and translational 
levels. Quantitative RT-PCR (Q-PCR) analyses using three 
pairs of PCR primers specific for FOXM1A, FOXM1B, and 
FOXM1C were conducted. In OVCA433 cells, FOXM1A 
was not detectable (after 45 cycles’ amplification). 
FOXM1C was expressed at low levels, which were not 
significantly up-regulated by LPA (P > 0.05). In contrast, 
FOXM1B was the major isoform that was expressed in 
OVCA433 cells and was up-regulated by LPA (Figure 3B).
FOXM1 was functionally involved in cell 
proliferation, migration, and invasion in EOC 
cells
The potential functional involvement of FOXM1 
in proliferation, migration, and invasion was first tested 
using thiostrepton, a FOXM1 inhibitor. Thiostrepton dose-
dependently reduced LPA-induced FOXM1 expression in 
OVCA433 cells (Figure 4A), which was accompanied 
by reduced cell migration and invasion in these cells 
(Figure 4B). To confirm these effects were indeed FOXM1 
mediated, we established shRNA-FOXM1 knock-down 
Figure 1: LPA induced FOXM1 up-regulation in EOC cells. A. OVCA433 cells were starved for 16 hr prior to LPA (10 μM) 
treatment for different times as indicated. B. OVCA433 cells were starved for 16 hr prior to LPA treatment (6 hr) with different concentrations 
as indicated. The bar figures on the right panels are the summary of three independent experiments. C. OVCA433 cells were transfected 
with siRNA against YAP. The down-regulation of YAP and the effect on LPA-induced FOXM1 are shown. The antibody used to detect 
FOXM1 was from Sigma (Cat. Log # AV39518). *P < 0.05; **P < 0.01 and ***P < 0.001.
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(KD) stable OVCA433 cell lines (KD-1 and KD-2; 
Figure 4C). Cell migration and invasion induced by LPA 
were inhibited in FOXM1 KD cell lines. In addition, FBS-
induced cell proliferation was reduced in FOXM1-KD1 
cell line (Figure 4D).
LPA-induced FOXM1 in additional EOC cell 
lines and FOXM1C was the dominant form in 
CAOV3 cells
LPA’s effect in FOXM1 was not limited to 
OVCA433 cells. As shown in Figure 5A, LPA (10 μM 
and 6 hr) treatment also induced FOXM1 up-regulation 
in CAOV3 and OVCAR5 cells. We used an anti-FOXM1 
antibody from Sigma (Cat. Log # AV39518) to detect 
FOXM1 (~80 KDa) in OVCA433 cells as shown in 
Figures 1–4 and Figure 5A. In the course of the study, 
we also used the anti-FOXM1 (D12D5, Cat. Log# 5436S) 
from Cell Signaling (Danvers, MA). Surprisingly, this 
antibody did not detect FOXM1 in OVCA433 cells, but 
detected a strong band in CAOV3 cells with an apparent 
molecular weight of ~100 KDa (Figure 5B).
FOXM1B and FOXM1C are 748 and 763 amino 
acid proteins, respectively. Our results showed that Sigma 
antibody only detected FOXM1B with an apparent MW ~80 
KDa and the Cell Signaling antibody detected FOXM1C 
with an apparent MW ~100 KDa (the increased MW may 
be contributed by both the increased amino acids and post-
translational modifications) (Figure 5C). shRNA-mediated 
knock-down of FOXM1 in OVCA433 (Figure 4C) and 
CAOV3 (Figure 5C) support that both of these bands 
are isoforms of FOXM1. To test this notion further, we 
conducted RT-Q-PCR analyses in these cells. As shown in 
Figure 5D, in contrast to OVCA433 cells, FOXM1C was 
the dominant isoform in CAOV3. In OVCAR5 cells, both 
FOXM1A and 1C forms were undetectable (after 45 cycles 
of PCR amplification) and FOXM1B was the major form, 
which was expressed in a relatively lower level than that 
in OVCA433 cells. A summary of the relative expression 
levels of the three FOXM1 isoforms in the three EOC cell 
lines is shown in Figure 5E.
Treatment with siRNA against YAP or PTX completely 
blocked the basal and LPA-induced FOXM1 expression 
in CAOV3 cells, suggesting that the Gi and YAP signaling 
pathways are both involved, similar to that in OVCA433 
cells (Figure 5F). In addition, FOXM1 KD in CAOV3 also 
reduced LPA-induced cell migration and invasion, and FBS-
induced cell proliferation in these cells (Figures 5G and 5H).
Figure 2: LPA1–3 and both of the PI3K and Rho pathways were involved in LPA-induced FOXM1. A. Pre-starved 
OVCA433 cells were treated with Ki16425 (10 μM) or Y27632 (10 μM) for 1 hr prior to LPA treatment (10 μM, 6 hr). FOXM1 was 
analyzed by Western blot. B. LPA (10 μM, 6 hr)-induced FOXM1 up-regulation were determined in LPA receptor specific siRNA-treated 
cells (48 hr post-transfection). C. Pre-starved OVCA433 cells were pretreated with PTX (100 ng/mL) for 16 hr; LY294002 (10 μM), 
U0126 (10 μM), or MK2203 (1 μM) for 1 hr, before LPA treatment for (10 μM, 6 hr). D. OVCA433 cells were starved overnight (16 hr), 
pretreated by OA(100 nM), C3(1 μg/mL), H89 (10 μM) for 1 hr, before LPA treatment for (10 μM, 6 hr). FOXM1 was detected using the 
Sigma antibody (Cat. Log # AV39518). The experiments were repeated at least three times. E and F. OVCA433 cells were transfected with 
dominant negative plasmids for 48 hr, starved and then treated with LPA (10 μM for 6 hr). Cell lysates were analyzed by Western blot. 
Representative results are shown. *P < 0.05; **P < 0.01; and ***P < 0.001.
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FOXM1 was functionally involved in 
tumorigenesis in vivo
We tested the roles of FOXM1 in vivo by i.p. 
injection of control-shRNA and FOXM1-shRNA 
transfected CAOV3 cells into NOD-SCID mice. The 
results are summarized in Figure 6. While all mice 
formed tumors, FOXM1 KD significantly reduced the 
tumor and ascites load in the mice. Figure 6A shows 
the representative pictures of the tumors formed in 
the control- and FOXM1-KD cell-injected mice. The 
tumor nodule numbers and sizes, and the tumors grew 
on the ovaries in particular, as well as ascites volumes 
were significantly reduced in FOXM1-KD cell injected 
mice, compared to control mice (Figures 6B and 6C). In 
addition, more organ sites were affected in control mice 
(Table 1, n = 5 mice in each group), suggesting that the 
reduced cellular activities (proliferation, migration, and 
invasion) in FOXM1-KD cells detected in vitro are likely 
contributing to the reduced tumoirgenesis in vivo.
We also determined and compared the levels of 
several FOXM1 targets in the blood, ascites, and/or 
tumors of the control- and FOXM1-KD cell-injected 
Figure 3: LPA-transcriptionally regulated FOXM1B in OVCA433 cells. A. The transcriptional inhibitor ActD (1 μg/mL, 1 hr 
pre-treatment) and the translational inhibitor CHX (20 μg/mL, 1 hr pre-treatment) inhibited LPA-induced FOXM1 up-regulation by LPA 
(10 μM, 6 hr). FOXM1 was detected using the Sigma antibody (Cat. Log # AV39518). B. The mRNA levels of FOXM1 isoforms in 
OVCA433 cells with or without LPA (10 μM, 6 hr) treatment. FOXM1A was not detectible after 45 cycles of PCR amplification. Real-time 
RT-PCR conditions were described in Methods. *P < 0.05; **P < 0.01; and ***P < 0.001.
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Figure 4: FOXM1 was functionally involved in cell proliferation, migration, and invasion in EOC cells. OVCA433 cells 
were starved and pretreated with different doses of thiostrepton (a selective inhibitor of FOXM1) for 1 hr prior to LPA treatment (10 μM, 
6 hr). Thiostrepton dose-dependently reduced LPA-induced FOXM1 expression A. and inhibited LPA-induced cell migration and invasion 
in OVCA433 cells B. FOXM1 down-regulation by shRNA C. reduced cell migration and invasion induced by LPA and cell proliferation 
induced by 2% FBS D. The results are from three independent experiments. FOXM1 was detected using the Sigma antibody (Cat. Log# 
AV39518). *P < 0.05; **P < 0.01; and ***P < 0.001.
Figure 5: LPA-induced FOXM1 in other EOC cell lines and FOXM1C was the dominant form in CAOV3 cells. A. LPA 
(10 μM and 6 hr) induced FOXM1 up-regulation in CAOV3 and OVCAR5 cells. CAOV3 and OVCAR5 cells expressed the FOXM1B 
with apparent MW of 80 KDa (Sigma, Cat. Log # AV39518). B. OVCA433 cells did not express FOXM1C, while CAOV3 cells expressed 
the FOXM1C with apparent MW of 100 KDa (Cell Signaling, Cat. Log # D12D5). C. CAOV3-FOXM1-KD cell line was established using 
shRNA against FOXM1 (detailed in Methods). The parental or control-shRNA transfected CAOV3 cells responded to LPA (10 μM, 6 hr) 
for FOXM1 up-regulation, which was blocked by KD-FOXM1. D. The dominant splicing form of FOXM1 in CAOV3 was FOXM1C. 
E. Comparison of the relative mRNA expression levels FOXM1 isoform in three EOC cell lines. F. KD-YAP and PTX inhibited LPA-
induced FOXM1 up-regulation in CAOV3 cells. G. KD-FOXM1 inhibited LPA-induced cell migration and invasion. H. KD-FOXM1 
inhibited FBS (2%)-induced cell proliferation. *P < 0.05; **P < 0.01; and ***P < 0.001.
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mice. FOXM1 regulates the expression of over 220 
genes [31]. We analyzed mRNA expression or protein 
secretion levels of several representative genes involved 
in proliferation, cell cycling, migration, or invasion, 
including: amphiregulin (ARGE), polo-like kinase 
1 (PLK1), aurora kinase B (AURKB), Rho-associated 
coiled-coil containing protein kinase 1 (ROCK1), uPA 
(plasminogen activator, urokinase; gene name PLAU), 
uPAR (plasminogen activator, urokinase receptor; gene 
name PLAUR), and vascular endothelial growth factor 
A (VEGFA) in paired tumors from the control shRNA-
transfected and FOXM1-KD cells derived tumors. As 
shown in Figure 6D, PLK1, AURKB, AREG, ROCK1, uPA 
and uPAR were significantly down regulated in FOXM1-
KD derived tumors. In addition, AREG and VEGF secreted 
in ascites and serum were significantly down regulated in 
KD cell injected mice (Figures 6E and 6F). Since human 
primers and ELASA kits were used, these changes in gene 
or protein levels are human tumor cell derived changes.
DISCUSSION
We show here, for the first time, that LPA is capable 
of regulating FOXM1 expression in EOC cells, which has 
not been shown in any other cell types. Interestingly, this 
regulation is mediated by both the Gi-PI3K and G12/13-Rho-
Figure 6: FOXM1 was functionally involved in tumorigenesis in vivo. A. Representative pictures of the tumors formed in Ctrl 
or FOXM1-KD cells injected mice. 7–10 weeks old female NOD/SCID mice were i.p. injected with 5 × 106 CAOV3 cells. Mice were 
euthanized 30 days after tumor cell injections and tumor development was analyzed. B. Tumor numbers and sizes were measured and 
compared. C. Effect of FOXM1-KD on CAOV3 generated ovarian tumor in NOD/SCID mice. D. FOXM1 related target genes were down-
regulated at the mRNA level in tumors from CAOV3-KD injected mice, when compared to those in tumors from control cells. E. Human 
AREG and VEGF were reduced in ascites, measured by ELISA F. Human AREG and VEGF were reduced in serum, measured by ELISA 
*P < 0.05, **P < 0.01, ***P < 0.001.
Table 1: Summary of ascites volume and metastasis invaded organs
Injected cells No. of Mice Ascites Incidence Ascites Volume 
(mean)
Tumor Incidence Invaded organs 
sites
CAOV3 5 3/5 0.2–0.4 ml 5/5 D.L.M.O.SI.W 
(all 5/5)
FoxM1-KD CAOV3 5 1/5 0.1 ml 5/5
D (4/5) 
W (4/5) 
M (2/5)
D, diaphragm; L, liver; M, mesentery; O, omentum; SI, small intestine; W, peritoneal wall.
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YAP pathways. In one of our previous publications, we used 
pharmacological inhibitors and genetic approaches to conduct 
detailed mechanistic studies of LPA and S1P-induced Akt 
activation in ovarian cancer cells. We have shown that the 
kinase activity and S473 phosphorylation of Akt induced by 
LPA and S1P requires both mitogen-activated protein (MAP) 
kinase (MEK) and p38 MAP kinase. MEK is likely to be 
upstream of p38 in the 9 cell lines examined [32]. Other 
than one report in malignant mesothelioma (MM) cells 
[16], this is the first evidence that YAP is an important up-
stream regulator of FOXM1 in epithelial cancer cells. The 
Hippo-YAP pathway has emerged as a critical oncogenic 
pathway in recent years [17–19]. Our work has linked the 
oncolipid LPA, the oncogenic YAP pathway, and the FOXM1 
network (which has been shown to be altered in 84% cases of 
HGSC) in EOC cells, providing a base for developing novel 
therapeutics for EOC.
Our results suggest that each of the three LPA 
receptors, LPA
1–3
, is essential for the action of LPA. 
Ki16425, a selective antagonist of LPA
1
/LPA3 also 
completely blocked the effect of LPA. In addition LPA
2
 
was also involved. We have previously shown that LPA 
receptors form homo- and hetero-dimers within the LPA 
receptor subgroup [33]. The results in this work suggest 
that these dimers may be functionally involved in LPA’s 
actions. Hence, each of them is essential for LPA’s action.
FOXM1 is a key regulator of over 200 genes 
involved in cancers [31]. We analyzed mRNA expression 
or protein secretion levels of several representative genes 
involved in proliferation and cell cycling, including 
ARGE, PLK1, AURKB, as well as several others likely 
to be involved in cell migration and/or invasion, such as 
ROCK1, uPA, uPAR, and vascular endothelial growth 
factor A (VEGFA), in paired tumors from the control 
shRNA-transfected and FOXM1-KD cell derived tumors. 
All of these genes/proteins have already been linked to 
tumor development of EOC. Other than the well-known 
functions of AREG, uPA, uPAR, and VEGF, aurora 
kinases B was not detected in non-neoplastic ovaries 
(n = 18), but almost all (79/80; 99%) ovarian carcinomas 
exhibited aurora-B positive tumor cells [34]. PLK1 and 
ROCK1 are also over-expressed in malignant ovarian 
tissues and/or functionally involved in EOC [35–37]. 
These results support not only the specific effects on 
FOXM1 in FOXM1-KD cells, but also on the molecular 
basis to target the FOXM1 network in EOC.
FOXM1 is a typical proliferation-associated 
transcription factor that is intimately involved in 
tumorigenesis. The important roles of FOXM1 in EOC 
have been implicated in previous studies [1, 2, 4–6]. 
Although the effect of a FOXM1 selective inhibitor, 
thiostrepton, has been tested in in vivo [5], the concept 
of targeting FOXM1 in EOC needs to be tested further 
since the mouse model and reagents used may improperly 
address the targeting issues related to FOXM1, due to the 
potential off-target effect of the inhibitor, the non HGSC 
nature of the cell line used (A2780 or SKOV3); and the 
route of the injection (s.c.) [5, 14]. In addition, specific 
tumor cell targeting may be necessary.
Our studies using shRNA-mediated KD of FOXM1 
in EOC cells have more specifically demonstrated the role 
of FOXM1 in cell proliferation, migration, and invasion 
in vitro and tumorigenesis in vivo. While pharmacological 
inhibitors are most commonly used for cancer treatment, 
all inhibitors have off targets. Our in vitro signaling results 
suggest that although several inhibitors used blocked the 
LPA-induction effects, they may increase the basal levels 
of FOXM1, which is an unwanted effect. Moreover, 
inhibitors also target host cells, which may result in 
toxicity. In recent years, other forms of therapeutics have 
been moving into clinical practice, including neutralizing 
antibodies and shRNA-mediated specific gene down 
regulation.
The three EOC cells lines used in this work may 
represent HGSC better than other EOC cell lines used in 
previous FOXM1 work. Recently, the most commonly 
used EOC cell lines, including A2780 and SKOV3, have 
been considered as non-HGSC cell lines [14, 38] based 
on genetic and functional characterizations. CAOV3 cells 
are considered “likely to be HGSC” [9]. OVCA433 and 
OVCAR5 cells are not included in the two sets analyses, 
but these cells have been shown to be serous cancer cell 
lines with a dysfunctional p53 pathway [39, 40], one of 
the most commonly shared features of HGSC cells. In 
addition, we used the i.p. injection (vs. the s.c. model in 
the previous studies using A2780 cells) [5] model in the 
present work to better recapitulate EOC metastatic disease.
Human FOXM1 is expressed in three distinct 
splice variants, which arise from the same gene through 
differential splicing of the two facultative exons A1 and 
A2 [31]. The resulting proteins are 801, 748, and 763 for 
FOXM1A, 1B and 1C, respectively. While FOXM1A is 
transcriptionally inactive in most cells, both FOXM1B and 
FOXM1C are biologically active, and they play similar 
biological roles. However, their expression patterns are 
cell type-dependent and their regulations and biding 
partners may differ [31]. FOXM1C has been found to 
be the predominant form expressed in pancreatic tumors 
and cancer cell lines [41]. Interestingly, we have found 
that FOXM1 isoform expression pattern is cell line-
dependent. Both the FOXM1B and FOXM1C forms were 
functionally involved in cell proliferation, migration, and 
invasion. In addition, LPA was able to up-regulate both 
forms in a cell line-dependent manner. Unexpected, the 
Sigma and Cell Signaling FOXM1 antibodies appear 
to only recognize the 1B or the 1C form, respectively 
(Figure 5B), even though both antibodies should recognize 
both forms theoretically. The immunogen peptide 
(KTSPRRPLILKRRRLPLPVQNAPSETSEEEPKRSPA 
QQESNQAEASKEVA) used for generating the Sigma 
antibody is present in both 1B and 1C forms (the first 51 
AA in both forms). The Cell Signaling FOXM1 antibody 
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is a monoclonal antibody against human recombinant 
FOXM1 protein, which typically detects FOXM1 as a 
100 kDa protein. Although this antibody is predicted 
to recognize FOXM1B (Cell Signaling Data sheet), 
we did not detect any bands between 50–110 KDa in 
OVCA433 cells (Figure 5B), suggesting that even if it 
might be recognizing FOXM1B, its sensitivity is low. 
While the reasons why these antibodies showed 1B and 
1C specificity are unclear, they are useful in isoform 
specificity studies.
Taken together, our data support the development of 
new EOC therapeutics centering at the FOXM1 network, 
including identified up-stream regulators and down-stream 
targets. Tumor cell specific targeting may be necessary and 
tumor and or tumor-host interaction generated secreted 
factors, such as AREG and/or VEGF may be used as 
follow-up factors to monitor treatment and diseases 
progression.
MATERIALS AND METHODS
Reagents
Oleoyl-LPA was purchased from Avanti Polar Lipids 
(Birmingham, AL). The following inhibitors or reagents 
were used in this study: LY294002 (Enzo Life Sciences, 
Farmingdale, NY); MK2206 and Y27632 (Biovision, 
Milpitas, CA); C3 exoenzyme (Cytoskeleton, Denver, 
CO); Ki16425 and okadaic acid (OA; Calbiochem, 
San Diego, CA); pertussis toxin (PTX; Invitrogen, 
Grand Island, NY); and actinomycin D (ActD) and 
cyclohexamide (CHX; Sigma-Aldrich, St. Louis, MO). 
Alexa fluor-conjugated secondary antibodies were from 
Life Technologies, Grand Island, NY. The dominant 
negative (dn) and constitutive active (ca) forms of large 
and small G protein constructs were from UMR cDNA 
Resource Center (Rolla, MO). The antibody mainly 
against FOXM1b was purchased from Sigma (Cat. Log. # 
AV39518). The antibodies against phospho-YAP (Ser127) 
and FOXM1C (D12D5, Cat. Log# 5436S) were purchased 
from Cell Signaling (Danvers, MA). The antibody against 
Total-YAP was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA).
Cell lines and culture
The OVCA433 cell line was a kind gift of Dr. R. 
Bast (M.D. Anderson); the CAOV3 and the OVCAR5 
cells were obtained from ATCC (Manassas, VA). All cell 
lines were maintained in a humidified atmosphere at 37°C 
with 5% CO
2
. OVCA433 cells were cultured in RPMI 
1640 with glutamine, 10% FBS (ATCC, Manassas, VA), 
and 100 μg/mL penicillin/streptomycin (P/S). CAOV3 
were cultured in DMEM with glutamine, 10% FBS 
(ATCC, Manassas, VA), and 100 μg/mL P/S. OVCAR5 
cells were cultured in DMEM with glutamine, 10% FBS 
(ATCC, Manassas, VA), 0.1 mM MEM Non-Essential 
Amino Acids (NEAA), 2 mM L-glutamine and 100 μg/
mL P/S. For serum starvation, cells were incubated in the 
basal medium without FBS or antibiotics. LPA treatment 
was always in cells starved from serum for 16 hr.
Western blot analysis
Western blot analyses were conducted using 
standard procedures and proteins were detected using 
primary antibodies and fluorescent secondary antibodies 
(IRDye 800CW-conjugated or IRDye 680-conjugated 
anti-species IgG, Li-Cor Biosciences, Lincoln, NE). 
The fluorescent signals were captured on an Odyssey 
Infrared Imaging System (Li-Cor Biosciences, Lincoln, 
NE) with both 700- and 800-nm channels. Boxes were 
manually placed around each band of interest, and the 
software returned near-infrared fluorescent values of 
raw intensity with background subtraction (Odyssey 3.0 
analytical software, Li-Cor Biosciences, Lincoln, NE). 
The protein MW marker used was the Prestained SDS-
PAGE Standards, broad range (BIO_RAD, Cat. Log # 
161–0318).
DNA and RNA transfection
Plates (6-well) were seeded with 5 × 104 cell/
well in 2 mL media 24 hr before transfection; cells were 
80%–90% confluent and were transfected with siRNA 
(100 pmol/well) or plasmid DNA (4 μg/well) using 
Lipofectamine 2000 Reagent (Life Technologies, Grand 
Island, NY) according to manufacturer’s instruction. After 
48 hr of transfection, cells were starved for migration and 
invasion assays. All siRNAs were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA).
Establish stable clones and drug selection 
concentrations
FOXM1 shRNA lentiVirus vectors with GFP 
(OriGene, Rockville, MD) were transfected to 293T cells 
for virus packaging. OVCA433 or CAOV3 cells were 
infected by virus 3 times and stable clones were selected 
by puromycin (concentration 0.5 μg/mL) for 10 days.
Reverse-transcription quantitative real-time 
PCR
Cells were washed with cold PBS and collected 
in the Qiagen RLT lysis buffer (Qiagen, Valencia, CA). 
RNA was extracted with the RNeasy mini kit (Qiagen, 
Valencia, CA) and reverse transcribed by M-MLV reverse 
transcriptase. Quantitative real-time PCR was performed 
on a Light Cycler 480 (Roche, Indianapolis, IN) with a 
SYBR Green I Master Mix (Roche, Indianapolis, IN). 
mRNA abundance was normalized to GAPDH. Negative 
controls contained no reverse transcription or the 
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reverse transcriptase. RNAs from triplicate cell pellets 
per condition were analyzed. Relative gene expression 
was calculated using the method given in Applied 
Biosystems User Bulletin No.2 (P/N 4303859B), with 
non-targeting siRNA-treated cells acting as the control 
in each data set. Primer pairs used in this study were: 
GAPDH: F, 5′-CACCATTGGCAATGAGCGGTTC-3′/R, 
5′-AGGTCTTTGCGGATGTCCACGT-3′; FOXM1A: F, 
5′-TGGGGAACAGGTGGTGTTTGG-3′/R, 5′-GCTAG 
CAGCACTGATAAACAAAG-3′; FOXM1B: F, 5′-CCAG 
GTGTTTAAGCAGCAGA-3′/R, 5′-TCCTCAGCTAGCA 
GCACCTTG-3′; FOXM1C: F, 5′-CAATTGCCCGAGCA 
CTTGGAATCA-3′/R, 5′-TCCTCAGCTAGCAGCACC 
TTG-3′. PLK1: F, 5′-CTCCTGGAGCTGCACAAGAG 
GAGGAA-3′/R, 5′-TCTGTCTGAAGCATCTTCTGGA 
TGAG-3′; AURKB: F, 5′-CTGCCATGGGAAGAAGG 
TGATTCA-3′/R, 5′-GATGCGGCGATAGGTCTCGTT 
G-3′; AREG: F, 5′-GTGGTGCTGTCGCTCTTGATA-
3′/R, 5′-ACTCACAGGGGAAATCTCACT-3′; ROCK1: 
F, 5′-GACCTGTAACCCAAGGAGAT-3′/R, 5′-GGAAAG 
TGGTAGAGTGTAGG-3′. uPA: F, 5′-CACGCAAGGGG 
AGATGAA-3′/R, 5′-ACAGCATTTTGGTGGTGACTT-3′. 
uPAR: F, 5′-CAACGACACCTTCCACTTC-3′/R, 5′-GCA 
CAGCCTCTTACCATATAG-3′.
Migration assays
To measure cell migration, the undersurfaces of 
Transwells (Costar, Corning, NY) were coated with collagen 
IV (10 μg/mL, Upstate Biotechnology, Lake Placid, NY) at 
4°C overnight. Coated transwells were then placed into a 
24-well plate containing 0.5 mL of serum-free medium. To 
determine the effect of FoxM1 in LPA induced migration, 
cells were starved and pretreated with thiostrepton (10 μM) 
prior to treatment with LPA (10 μM, 6 hr); detached cells (by 
PBS containing 10 mM EDTA) were washed several times 
with serum-free medium. Cells (106 in 100 μL) in serum-free 
medium were added to the upper chamber in each transwell 
and allowed to migrate for 4 hr at 37°C. LPA (10 μM) were 
added to the lower chamber as the chemoattractant. Cotton 
swabs were used to remove cells in the upper surface of the 
transwells, and migratory cells attached on the undersurface 
were stained with crystal violet solution. Transwells were 
rinsed with water and air-dried. Crystal violet-stained 
attached cells were solubilized in 100 μL of 10% acetic acid 
and quantitated using a microplate reader at 600 nm.
Invasion assays
Inner side of Transwells (8 μM pore size) were coated 
with Matrigel at a concentration of 1.1 μg/mL and placed 
in a modified Boyden chamber. Serum starved (24 hr) cells 
were treated w/o LPA (10 μM, 6 hr), then trypsinized and 
1.5 × 105 cells/well were added to the top chamber. LPA 
(10 μM) served as a chemoattractant and was added to the 
lower chambers. Cells were allowed to invade through the 
Matrigel barrier for 24 hr. After incubation, filters were fixed 
and stained in Diff-Quick staining solutions. Non-invading 
cells were removed using a cotton swab while invading 
cells on the underside of the filter were enumerated using 
an inverted microscope. All experiments were performed in 
triplicate and repeated at least three times.
Proliferation assay
Cells were seeded in 96-well plates (2000 cells/
well), cultured for 48 hr, and then starved for 24 hr by 
replacing the media with serum-free media (RPMI 1640 
for OVCA433 cells and DMEM for CAOV3 cells), 
followed by addition of 2% FBS, in the presence or 
absence of thiostrepton (10 μM). The cells were further 
cultured for 48 hr. Cell proliferation was evaluated by 
MTT hydrolysis using Cell Counting Kit-8 (Dojindo 
Molecular Technologies, Rockville, MA).
ELASA assays
Ascites and serum were collected from NOD/SCID 
mice (either CAOV3 control or FOXM1-KD CAOV3 
cells injected) and stored at −80°C until ELISA assays 
were conducted. ELISA assays were performed using 
ELASA kits from the Human ELISA Development 
Systems (R&D Systems. Minneapolis, MN) in triplicate 
wells according to the manufacturer’s instructions. The 
optical density at 450 nm was measured on an automated 
plate reader (PerkinElmer, Santa Clara, CA). Experiments 
were repeated three times.
Xenograft mouse model
Female NOD/SCID mice were obtained from the 
In vivo Therapeutics Core, Indiana University School of 
Medicine (Indianapolis, IN) at 7 to 10 weeks of age. CAOV3 
cells (both FOXM1-KD and control cells, 5 × 106 in 500 μL 
of PBS) were i.p. injected into mice. Tumors were monitored 
in living mice every day. Mice were euthanized 30 days after 
tumor cell injections, and tumor development was analyzed. 
Tumors were counted at each metastatic location, and tumor 
diameters were measured. Ascites were collected from 
NOD/SCID mice and, after centrifugation, floating living 
tumor cells (GFP-expressing cells) were counted. Animal 
protocols were approved by the Indiana University School 
of Medicine Animal Care and Use Committee.
Statistical analyses
The Student’s t-test was utilized to assess the 
statistical significance of the difference between two 
treatments. The asterisk rating system as well as quoting 
the P value in this study was *P < 0.05; **P < 0.01; and 
***P < 0.001. A P value of less than 0.05 was considered 
significant.
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